Olumiant (Baricitinib) Patent Expiration, LOE Window & CMS Spending
Olumiant (Baricitinib) by Eli Lilly: FDA Orange Book core substance LOE 2032-05-31 (last listed 2032-11-30), 1 AB generics, $68.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eli Lilly |
| FDA Application & Pathway | N207924 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-05-31 |
| Last Listed Patent or Exclusivity Date | 2032-11-30 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $68.1M |
| 2024 Medicare Part D Spend | $35.4M |
| 2024 Medicaid Spend | $32.7M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.